Form 8-K · Current Report · Filed 2026-04-30
Illumina Announces Strong Q1 2026 Financial Results and New Share Repurchase Program
Illumina, Inc. reported strong financial results for the first quarter of fiscal year 2026, with revenue of $1.09 billion, up 4.8% from Q1 2025. The company achieved a GAAP operating margin of 19.2% and a non-GAAP operating margin of 21.9%. GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.15. On April 28, 2026, the Board of Directors authorized a new share repurchase program for up to $1.5 billion of the Company's common stock, in addition to the existing $1.5 billion program from August 2024.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001110803-26-000087
- CIK
- 0001110803
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$120.37
Next session
+12.8%
Since filing
+70.4%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ILMN insiders reported 60 Form 4 transactions — net selling of $169.2M.
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.